Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Iohexol
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2013
Lead Product(s) : Iohexol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Taejoon Pharm. Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Chest CT Using Low-concentration Iodine Contrast Media
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Iohexol
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Taejoon Pharm. Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Bayer AG | GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2018
Lead Product(s) : Iohexol
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Bayer AG | GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2018
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2015
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable